Enzon Pharmaceuticals Inc (NASDAQ:ENZN) - Overview

Stock Report

Enzon Pharmaceuticals Inc ENZN

Last Price
$-

Day Change
-|-%

As of -
- | USD
Minimum 15 Minutes Delay.

Last Close-
Day Range-
Mkt Cap19.23Mil
52-Wk Range-
Yield %-
ISINUS2939041081
Volume-
P/E-
P/S-
P/CF-

Share Price

Financials
201320142015
More ...
Income Statement
Revenue34.4931.1717.46
Operating Income18.1628.7910.80
Net Income18.1528.8021.64
Basic EPS0.410.650.49
Avg. Diluted Shares Outstanding514444
Balance Sheet
Current Assets7.1235.0411.78
Non Current Assets0.000.0011.11
Total Assets7.1235.0422.89
Current Liabilities1.315.064.80
Total Liabilities1.875.444.80
Total Equity5.2629.6018.09
Cash Flow
Operating Cash Flow14.0132.3414.68
Capital Expenditure---
Free Cash Flow---

In millions, except "Basic EPS". Currency is USD.

Company Profile

Enzon Pharmaceuticals Inc is related to sales of drugs by various companies. It generates revenues from the sales of products namely, PegIntron, Sylatron, Macugen and CIMZIA.

Sector

Healthcare

Industry

Biotechnology

Fiscal Year Ends

December

Employees

1
Key Stats
More ...
Price/Earning TTM-
Price/Book-
Price/Sales TTM-
Rev Growth (3 year avg)-25.72
EPS Growth (3 year avg)-
Operating Margin % TTM61.87
Net Margin % TTM123.95
ROE TTM90.74
Debt/Equity-
Dividends
PreviousLatest
More ...
Declared Date30/06/1502/12/15
Ex-Div13/08/1530/12/15
Paid12/08/1529/12/15
Amnt0.500.25
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at Trafford House, Chester Road, Manchester M32 0RS. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2016 Morningstar. All rights reserved.